New Risk • Mar 20
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.9% Last year net profit margin: 3.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 41% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (₩57.2b market cap, or US$38.2m). Tillkännagivande • Mar 07
Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2026 Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 593-16, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea Upcoming Dividend • Dec 22
Upcoming dividend of ₩97.68 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Payout ratio is a comfortable 40% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%). Declared Dividend • Nov 13
Dividend of ₩97.68 announced Shareholders will receive a dividend of ₩97.68. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.4%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (46% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.0% per year over the past 6 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 49% to shift the payout ratio to a potentially unsustainable range, which is more than the 14% EPS decline seen over the last 5 years. Tillkännagivande • Nov 12
Seoulin Bioscience Co.,Ltd. announces Annual dividend, payable on April 20, 2026 Seoulin Bioscience Co.,Ltd. announced Annual dividend of KRW 97.6848 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩72.5b market cap, or US$52.7m). New Risk • Mar 25
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.5% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 22% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩55.8b market cap, or US$38.0m). New Risk • Mar 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (₩60.1b market cap, or US$41.2m). Tillkännagivande • Feb 21
Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2025 Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 593-16, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩97.66 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 28 April 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%). New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩70.3b market cap, or US$49.6m). Tillkännagivande • Aug 08
Seoulin Bioscience Co.,Ltd. (KOSDAQ:A038070) announces an Equity Buyback for KRW 1,000 million worth of its shares. Seoulin Bioscience Co.,Ltd. (KOSDAQ:A038070) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on February 6, 2025. As of August 6, 2024, the company had 293,246 shares in treasury within scope available for dividend and 55,397 shares in treasury through other repurchase. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: ₩66.00 (vs ₩211 in 1Q 2023) First quarter 2024 results: EPS: ₩66.00 (down from ₩211 in 1Q 2023). Revenue: ₩18.9b (down 17% from 1Q 2023). Net income: ₩564.6m (down 69% from 1Q 2023). Profit margin: 3.0% (down from 8.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Dec 20
Upcoming dividend of ₩127 per share at 1.4% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 40% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%). Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩67.00 (vs ₩144 in 3Q 2022) Third quarter 2023 results: EPS: ₩67.00 (down from ₩144 in 3Q 2022). Revenue: ₩19.6b (down 12% from 3Q 2022). Net income: ₩563.1m (down 53% from 3Q 2022). Profit margin: 2.9% (down from 5.4% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 19
Full year 2022 earnings released: EPS: ₩1,163 (vs ₩1,918 in FY 2021) Full year 2022 results: EPS: ₩1,163 (down from ₩1,918 in FY 2021). Revenue: ₩102.4b (up 27% from FY 2021). Net income: ₩9.51b (down 39% from FY 2021). Profit margin: 9.3% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 28% per year. Upcoming Dividend • Dec 21
Upcoming dividend of ₩97.56 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 9.4% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 15% share price gain to ₩14,100, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 80% over the past three years. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment improved over the past week After last week's 15% share price gain to ₩18,400, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 206% over the past three years. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improved over the past week After last week's 42% share price gain to ₩15,900, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 93% over the past three years. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩12,650, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 50% over the past three years. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Mar 13
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: ₩1,952 (up from ₩612 in FY 2020). Revenue: ₩80.7b (up 24% from FY 2020). Net income: ₩15.6b (up 219% from FY 2020). Profit margin: 19% (up from 7.5% in FY 2020). Revenue exceeded analyst estimates by 3.7%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩15,200, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 67% over the past three years. Upcoming Dividend • Dec 22
Upcoming dividend of ₩96.25 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. Payout ratio is a comfortable 4.5% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%). Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 16% share price gain to ₩23,500, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 178% over the past three years. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩25,650, the stock trades at a trailing P/E ratio of 34.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 180% over the past three years. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩31,700, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 42x in the Biotechs industry in South Korea. Total returns to shareholders of 237% over the past three years. Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improved over the past week After last week's 38% share price gain to ₩37,800, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 45x in the Biotechs industry in South Korea. Total returns to shareholders of 310% over the past three years. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improved over the past week After last week's 16% share price gain to ₩25,000, the stock trades at a trailing P/E ratio of 37.1x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 172% over the past three years. Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment improved over the past week After last week's 25% share price gain to ₩27,250, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 49x in the Biotechs industry in South Korea. Total returns to shareholders of 186% over the past three years. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment improved over the past week After last week's 16% share price gain to ₩21,900, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 42x in the Biotechs industry in South Korea. Total returns to shareholders of 129% over the past three years. Valuation Update With 7 Day Price Move • May 13
Investor sentiment improved over the past week After last week's 37% share price gain to ₩19,650, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 51x in the Biotechs industry in South Korea. Total returns to shareholders of 90% over the past three years. Reported Earnings • Mar 19
Full year 2020 earnings released: EPS ₩636 (vs ₩1,143 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩65.1b (up 20% from FY 2019). Net income: ₩4.89b (down 45% from FY 2019). Profit margin: 7.5% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Mar 09
New 90-day low: ₩12,000 The company is down 12% from its price of ₩13,667 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 14% over the same period. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩14,900, the stock is trading at a trailing P/E ratio of 28.1x, down from the previous P/E ratio of 33.6x. This compares to an average P/E of 57x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 40%. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 33% share price gain to ₩17,850, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 25.3x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 76%. Is New 90 Day High Low • Jan 06
New 90-day high: ₩17,850 The company is up 48% from its price of ₩12,031 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩93.52 Per Share Will be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.3%). Is New 90 Day High Low • Dec 14
New 90-day high: ₩14,650 The company is up 3.0% from its price of ₩14,250 on 15 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. Valuation Update With 7 Day Price Move • Nov 10
Market bids up stock over the past week After last week's 17% share price gain to ₩13,750, the stock is trading at a trailing P/E ratio of 26.1x, up from the previous P/E ratio of 22.3x. This compares to an average P/E of 66x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 28%. Is New 90 Day High Low • Oct 23
New 90-day low: ₩11,250 The company is down 11% from its price of ₩12,700 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 11% over the same period.